SCHEMBL75733

SCHEMBL75733

[c]1c[nH]c2ncccc12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6303892 0.72 KMT2A (0.46)
SCHEMBL2007656 0.70
SCHEMBL21545975 0.66 LMNA (0.50)
SCHEMBL27754782 0.66 CDK8 (0.51)
SCHEMBL2009078 0.65
SCHEMBL5217 0.65
SCHEMBL160264 0.65
SCHEMBL21250495 0.65
SCHEMBL2993525 0.65
SCHEMBL157846 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 3536 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118355015-A N- (5-substituted- [ (1, 3, 4-thiadiazole) or (thiazolyl) ]) (substituted) carboxamide compounds for inhibiting human polymerase θ and uses thereof 修复治疗公司 2024-07-16 CN claimed
EP-4392032-A1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME Arena Pharmaceuticals, Inc. (US) 2024-07-03 EP claimed
US-11987588-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2024-05-21 US claimed
WO-2024094170-A1 INHIBITOR OF UBIQUITIN-SPECIFIC PROTEASE 1 AND USE THEREOF 深圳晶泰科技有限公司 2024-05-10 WO claimed
EP-4361141-A1 PROTEIN DEGRADATION AGENT Suzhou Kintor Pharmaceuticals, Inc. (CN) 2024-05-01 EP claimed
US-20240124453-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2024-04-18 US claimed
US-20240101538-A1 PROTEIN-PROTEIN INTERACTION MODULATORS OF AURORA KINASE A AND THEIR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) 2024-03-28 US claimed
US-20240059691-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-02-22 US claimed
CN-117545749-A Protein degradation agent 苏州开拓药业股份有限公司 2024-02-09 CN claimed
WO-2024027694-A1 PROTEIN DEGRADATION AGENT 苏州开拓药业股份有限公司 2024-02-08 WO claimed
EP-0730578-A4 INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) MERCK & CO INC (US) 1997-10-08 EP claimed
US-5663171-A FOR USE IN HUMANS OR ANIMALS MERCK & CO., INC. (US) 1997-09-02 US claimed
US-5618821-A VIRICIDES, PICORNAVIRUS SANOFI, S.A. (FR) 1997-04-08 US claimed
US-5614518-A Morpholine derivatives as dopamine receptor subtype ligands MERCK SHARP & DOHME LTD. (GB) 1997-03-25 US claimed
EP-0730578-A1 INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) MERCK & CO. INC. (US) 1996-09-11 EP claimed
EP-0730593-A1 MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME LTD. (GB) 1996-09-11 EP claimed
EP-0497659-B1 Aryl(or Heteroaryl)-piperazinyl-alkyl-azole derivatives, their preparation and their application as drugs ESTEVE LABOR DR (ES) 1996-04-10 EP claimed
WO-1995031438-A1 THERAPEUTIC PHENOXYALKYLHETEROCYCLES SANOFI WINTHROP, INC. (US) 1995-11-23 WO claimed
WO-1995014690-A1 MORPHOLINE DERIVATIVES AS DOPAMINE RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME LIMITED (GB) 1995-06-01 WO claimed
WO-1995014666-A1 INDOLYL GROUP CONTAINING COMPOUNDS AND THE USE THEREOF TO PROMOTE THE RELEASE OF GROWTH HORMONE(S) MERCK & CO., INC. (US) 1995-06-01 WO claimed